Dr. Leuva is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2510 Bellevue Medical Center Dr
Ste 250
Bellevue, NE 68123Phone+1 402-559-8013
Summary
- Dr. Harshraj Leuva is an oncologist in Bellevue, NE and is affiliated with multiple hospitals in the area, including James J. Peters Veterans Affairs Medical Center and Nebraska Medicine - Nebraska Medical Center.. He specializes in genitourinary oncology and is experienced in prostate cancer and medical oncology. He has 7 publications and over 500 citations.
Education & Training
SUNY Downstate Health Sciences UniversityFellowship, Hematology and Medical Oncology, 2019 - 2022
Icahn School of Medicine at Mount Sinai (Bronx)Chief Residency, Internal Medicine, 2018 - 2019- Icahn School of Medicine at Mount Sinai (Bronx)Residency, Internal Medicine, 2015 - 2018
OtherClass of 2010
Certifications & Licensure
NE State Medical License 2022 - 2026
NY State Medical License 2018 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award American Society of Clinical Oncology (ASCO), 2021
Publications & Presentations
PubMed
- 333 citationsEltrombopag Added to Standard Immunosuppression for Aplastic Anemia.Danielle M. Townsley, Phillip Scheinberg, Thomas Winkler, Ronan Desmond, Bogdan Dumitriu
The New England Journal of Medicine. 2017-04-19 - 22 citationsPredictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia.Emma M Groarke, Bhavisha A Patel, Ruba Shalhoub, Fernanda Gutierrez-Rodrigues, Parth Desai
Leukemia. 2022-09-01 - 16 citationsA novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enza...Harshraj Leuva, Keith Sigel, Mengxi Zhou, Julia Wilkerson, David H. Aggen
Seminars in Oncology. 2019-08-01
Lectures
- The rate of tumor growth, g, as a biomarker for overall survival (OS) in prostate cancer (PC) in clinical trials as well as in real-world data from the Veterans Admini...2019 ASCO Annual Meeting - 6/1/2019
- A novel approach to mine the Veterans Administration Informatics and Computing Infrastructure (VINCI) allows one to assess the efficacy of cancer therapies: Abirateron...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
